FATE Stock Analysis: Buy, Sell, or Hold?

FATE - Fate Therapeutics, Inc.

BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
$2.16
0.01 (0.47%) ▲
5d: +7.46%
30d: +2.86%
90d: +87.83%
BUY
MODERATE Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 11, 2026

Get Alerted When FATE Hits Your Target Price

Join 10,000+ traders who never miss a move

You're in! Check your email to confirm and set your target price.
100% Free No spam, ever Unsubscribe anytime

Interactive Price Chart (1 Month)

Loading chart...

Loading historical data...

💡
Bottom Line:
💡 BUY OPPORTUNITY: FATE shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
See Forward Earnings Fair Value & Price Prediction →

In-depth Analysis How we analyze

Valuation Analysis: FATE is currently trading at $2.16, which is considered fair relative to its 30-day fair value range of $1.84 to $2.41.

Technical Outlook: Technically, FATE is in a strong uptrend. Immediate support is located at $1.82, while resistance sits at $2.88.

Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $5.41 (+150.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.

Quick Decision Summary

Current Position FAIR
Historical Trading Range $1.84 - $2.41
Company Quality Score 55/100 (HOLD)
Volume Confirmation HIGH
Confidence Score 74.7%

All Signals

  • NEUTRAL: Price in fair range
  • NEUTRAL: Mixed technical signals (40/100)
  • BULLISH: High volume confirmation
  • BULLISH: Trading 150.5% below Wall St target ($5.41)

Trading Range Analysis

30-Day Trading Range $1.84 - $2.41
Current vs Trading Range FAIR

Support & Resistance Levels

Support Level $1.82
Resistance Level $2.88
Current Trend Strong Uptrend
Technical data as of Jun 9, 2026

Fundamental Context

Forward P/E (Next Year Est.) -2.18
Wall Street Target $5.41 (+150.5%)
Revenue Growth (YoY) -20.3%
Share & Embed Analysis

Found this analysis useful? Share it with your community or embed the live chart on your blog.

Tweet Reddit
bloggers & journalists: you are free to use our charts with attribution.
Last updated: June 23, 2026 5:04 PM ET
Data refreshes hourly during market hours. Next update: 6:04 PM
🔥 Top Stocks Breaking Out Now
Ticker Score Recommendation Change %
Technical Signals Check
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Bahram Valamehr SELL 5190 shares 2026-01-09
Cindy Tahl SELL 10589 shares 2026-01-09

Unlock Insider Activity

See real-time buying/selling by company executives for FATE.

Create Free Account

Already have an account? Log In

Top Rated Biotechnology Stocks

Top-rated stocks in Biotechnology by analyst ratings.

Stock Analyst Consensus Analyst Target Tradestie Score
SRPT
Sarepta Therapeutics Inc
STRONG BUY
26 analysts
$22 54 HOLD
NRIX
Nurix Therapeutics Inc
STRONG BUY
18 analysts
$31 62 BUY
BNTX
BioNTech SE
STRONG BUY
21 analysts
$122 55 HOLD
DYN
Dyne Therapeutics Inc
STRONG BUY
14 analysts
$38 62 BUY
DNTH
Dianthus Therapeutics In…
STRONG BUY
12 analysts
$128 57 HOLD

More Analysis for FATE

FATE Technical Chart FATE Price Prediction FATE Earnings Date FATE Investment Advisor FATE Fair Price Analyzer FATE Competitors
Live Trades
From trading groups
Loading trades...
View All Live Trades See Trader Consensus & Signals